Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate [SUBSTUDY of 700028860]

Trial Profile

Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate [SUBSTUDY of 700028860]

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms MTR-IR
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top